0001830487-26-000013
SEC filingPharvaris advanced deucrictibant through pivotal Phase 3 trials and late-stage CMC scale-up in 2025, maintaining strategic focus on dual on-demand and prophylactic development paths while operating under the financial discipline of its 2021 Equity Incentive Plan and multi-CDMO supply framework.
In FY 2025, Pharvaris completed the RAPIDe-3 trial and continued enrollment in CHAPTER-3 — both pivotal Phase 3 studies evaluating deucrictibant for hereditary angioedema. The analysis of secondary endpoints confirmed clinically meaningful improvement in attack severity and a decrease in attacks treated with on-demand medication. This evidence strengthens the therapeutic profile beyond the primary endpoint and informs ongoing regulatory engagement across major markets.
Late-stage development necessitated parallel investment in CMC scale-up and supply readiness. As noted in management commentary, leadership responsibility explicitly includes global supply chain and CMC activities — reflecting the integration of these functions into the core execution plan. The company maintains two CDMOs for deucrictibant API production, a deliberate design to mitigate supply concentration risk and support continuity through clinical and potential commercial demand.
The 2021 Equity Incentive Plan continues to serve as the foundational framework for director and employee retention and alignment. Its structure is purpose-built to sustain leadership continuity through the transition from late-stage development to potential commercial launch — a period requiring consistent scientific, regulatory, and operational judgment.
Management acknowledges intensifying pressure from public and private payers, including market access constraints, pricing controls, and mandatory discounting. These dynamics are not speculative but reflect observable trends in healthcare reimbursement environments globally. Their anticipated escalation directly informs Pharvaris’ pre-launch health economics, outcomes research, and payer engagement strategy.
Supply chain resilience remains a material operational priority. The risk factors explicitly identify potential delays arising from unexpected loss of supply or CDMO capacity limitations — risks that could impact clinical timelines or commercial readiness. This acknowledgment underscores the centrality of supply assurance to the company’s near-term execution plan and reinforces why dual CDMO arrangements are operationally embedded, not merely contractual contingencies.